A Rising PSA on a Drug That's Supposed to Suppress It
His PSA doubled while on finasteride — a number the standard correction rule turns into a concerning value, built from a population average nobody has validated against him specifically.
F.B., 68, has spent the last four years as the primary caregiver for his wife, who has moderate dementia — a role that leaves him, by his own account, with little bandwidth to worry about his own health beyond keeping his annual physical. He has taken finasteride 5mg daily for BPH for that same four years, with his PSA tracked yearly and stable in the 1.0 to 1.2ng/mL range, consistent with the roughly fifty percent suppression finasteride is expected to produce at steady state. This year's value came back at 2.0ng/mL, nearly doubling from last year's 1.1 — which, corrected by the standard doubling convention used for men on a 5-ARI, translates to an estimated unsuppressed value near 4.0, a threshold that would prompt further workup in an untreated man his age.
He has no urinary symptom change to explain a benign PSA fluctuation, no recent infection, no instrumentation, and no family history of prostate cancer that he's aware of. His prior PSA readings had been remarkably flat year over year, which is part of what makes this year's jump stand out rather than read as ordinary lab variability. He is otherwise well — controlled type 2 diabetes on metformin, no cardiovascular disease — and the appointment where this result came back was, by coincidence, one of the rare visits he'd scheduled for himself rather than squeezed in around his wife's care, which is part of why the number landed with more weight than a routine lab result usually would.
How much to trust the doubled number
A corrected value near 4.0, in a man whose PSA had been flat for four years, is exactly the kind of change I'd want worked up in anyone. PCPT itself found a troubling wrinkle worth remembering here: cancers detected in men on finasteride skewed toward higher grade. Whatever that finding ultimately reflects, it argues against waiting on a rise like this.
I'd flag one thing before we act on that corrected number as though it were measured directly. The doubling rule comes from average suppression across a trial population — nobody ever measured his individual suppression percentage against his own pre-treatment baseline, because he'd already started the drug before his PSA was ever tracked. A number built from a population average, applied to one man, deserves less certainty than we're currently giving it.
I'm not arguing against workup — I'm arguing against treating "4.0" as a measured fact rather than an estimate with real uncertainty attached to it.
Then let's not lean on the doubling math at all. His PSA rose from 1.1 to 2.0 in one year after four years of being flat — that's a velocity finding, and velocity is an independently validated referral trigger in untreated men regardless of any correction factor. Whether the "true" number is exactly 4.0 or somewhat different, a drug that's supposed to be suppressing his PSA just failed to keep it flat. That's the signal that matters, and it doesn't depend on either of you being right about the doubling rule.
Agreed: proceed with urgent urologic referral — free/total PSA ratio and consideration of MRI — based on the year-over-year trend, without discontinuing finasteride first.
Not agreed: whether his PSA monitoring interval should shorten permanently going forward or return to the prior annual cadence once this specific workup resolves. The urologic oncologist favors closer monitoring indefinitely given this year's finding; the primary care physician would rather decide that once the workup's actual result is known.